Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.
Lead Product(s): Naproxen Sodium,Sumatriptan
Therapeutic Area: Neurology Product Name: Suvexx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Orion Corporation
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 15, 2023